drug · small molecule
milvexian
Phase 3updated 5mo agoby Bristol-Myers Squibb Co🔗 ChEMBL
Phase 3community read0 votes
Small molecule drug with a maximum clinical stage of Phase 3 (across all indications), with 5 investigational indications.
indications
indications
Atrial Fibrillation
targets
Coagulation factor XI
all catalysts(0)
nothing on the calendar yet
Trials studying milvexian
- phase3A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
- phase3A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
- phase3A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
- phase1A Study to Assess the Reversal of the Anticoagulant Effects of Milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy Participants
- phase1A Study of JNJ-70033093 (Milvexian) in Healthy Adult Participants
- phase1A Study of Milvexian in Healthy Adult Females
- phase1A Study Evaluating Drug Drug Interaction Between Milvexian and Atorvastatin in Healthy Participants
News(10)
- BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffsBMO Capital Markets is more impressed by Merck’s plans to replace lost Keytruda revenue than on Bristol Myers Squibb’s efforts to fill the expected void that will come from loss of exclusivity for…biospace · 2d ago
- BMS reports liver injury events in lung disease program, with key readout nearBristol Myers Squibb will soon release Phase 3 data for admilparant that could make or break Contineum Therapeutics’ rival product. But reports of a death due to liver injury in the pharma’s progra…biospace · 3d ago
- Stripped of AstraZeneca safety net, BMS could face ‘carnage’ if high-risk clinical trial failsBMS is barreling toward a clinical trial readout that an H.C. Wainwright analyst believes could contribute to the return of mergers between mega-cap drugmakers.biospace · 1mo ago
- BMS welcomes new multiple myeloma drug as generics batter current portfolioThe FDA approves Zenbexus just as copycat competitors depress sales of Bristol Myers Squibb’s multiple myeloma drugs Pomalyst and Revlimid, which crashed 71% and 49% year-on-year, respectively, in…biospace · 1mo ago
- As portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca mergerWhile both drugmakers face looming patent cliffs, analysts say joining forces could help Bristol Myers Squibb replenish its eroding portfolio—while the strategic case for AstraZeneca seems to be mo…biospace · 2mo ago
- An AstraZeneca-Bristol Myers megamerger? Wall Street isn’t thrilled.In fact, the former lost tens of billions of dollars in market value following reports of a potential tie-up between the pharmaceutical giants.biopharma_dive · 2mo ago
- Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOsSanofi wants to broaden the company’s productive partnership with Regeneron, its CEOs said. Elsewhere, Bristol Myers delayed two anticipated study readouts and a Shionogi-backed startup went public.biopharma_dive · 2mo ago
- BMS’ ‘big beat’ clouded by Cobenfy, heart disease data delaysStrong quarterly results are prompting Bristol Myers Squibb to lift its 2026 outlook, though the company is facing another delay for key Cobenfy Alzheimer’s data and a pushed-back readout for milve…biospace · 2mo ago
- BMS CEO Boerner doesn’t ‘feel any compulsion to chase deals’ despite lack of M&A this yearBMS may have been absent from the dealmaking spree of some of its Big Pharma peers this year, but that might not change anytime soon.fiercebiotech · 2mo ago
- Bristol Myers delays Cobenfy Alzheimer’s psychosis readout again amid another quarterly beatInvestors awaiting Bristol Myers Squibb’s key Alzheimer’s psychosis readout for Cobenfy and atrial fibrillation data for milvexian will have to wait a little longer.fiercebiotech · 2mo ago
Data sources
last refreshed 15m ago
Found something off?
comments(0)
5-min edit window · permanent after that